References
- Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295–300.
- Stumvoll M, Golstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333–46.
- Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.
- Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–93.
- Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331–6.
- Göttlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992;89:4653–7.
- Leff T, Reed JE. The antidiabetic PPARγ ligands: an update on compounds in development. Curr Med Chem Imunol Endocr Metab Agents 2002;2:33–47.
- Henke BR. Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes. J Med Chem 2004;47:4118–27.
- Rubenstrunk A, Hanf R, Hum DW, Fruchart J-C, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065–81.
- Fiévet C, Fruchart J-C, Staels B. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006;6:606–14.
- Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21:687–710.
- Caijo F, Mosset P, Grée R, Audinot-Bouchez V, Boutin J, Renard P, et al. Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs. Bioorg Med Chem Lett 2005;15:4421–6.
- Caijo F, Mosset P, Grée R, Audinot-Bouchez V, Boutin J, Renard P, et al. Synthesis of aromatic analogs of 8(S)-HETE and their biological evaluation as activators of the PPAR nuclear receptors. Eur J Org Chem 2006:2181–96.
- Kerry MA, Boyd GW, Mackay SP, Meth-Cohn O, Platt L. The synthesis of benzo[h]quinolines as topoisomerase inhibitors. J Chem Soc Perkin Trans 1 1999:2315–21.
- Ferry G, Bruneau V, Beauverger P, Goussard M, Rodriguez M, Lamamy VO, et al. Binding of prostaglandins to human PPARγ: tool assessment and new natural ligands. Eur J Pharmacol 2001;417:77–89.
- Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998;393:790–3.
- Grée R, Liutkus M, Caijo F, Brioche J, Jennequin T, Dacquet C, et al. Preparation of heterocycles, in particular 3-[(alkynyl)(hydroxy)methyl]-2-phenylalkoxyquinolines, pharmaceutical compositions containing them, and their use in the treatment of type II diabetes and obesity. PCT Int. Appl. WO/2008/081096. Geneva: WIPO, 2008.
- Liutkus M, Dacquet C, Audinot-Bouchez V, Boutin J, Caignard D-H, Ktorza A, et al. Synthesis of a novel series of 8-HETE analogs and their biological evaluation towards the PPAR nuclear receptors. Lett Drug Des Discov 2008;5:503–11.